エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of March 2024
Commission File Number: 001-38104
IMMURON LIMITED
(Name of Registrant)
Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-Immuron Limited (the “Company”) published one announcement (the “Public Notices”) to the Australian Securities Exchange on March 5, 2024 titled:
IMMURON LIMITED
EXPLANATORY NOTE
| - | “Trading Halt” |
A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.
This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
EXHIBITS
| Exhibit
Number |
Description | |
| 99.1 | Trading Halt |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IMMURON LIMITED | ||
 |
||
| Date: March 5, 2024 | By: | /s/ Phillip Hains |
| Phillip Hains | ||
| Company Secretary | ||
Exhibit 99.1
Market Announcement
5 March 2024
Immuron Limited (ASX: IMC) – Trading Halt
Description
The securities of Immuron Limited (‘IMC’) will be placed in trading halt at the request of IMC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 7 March 2024 or when the announcement is released to the market.
Issued by
ASX Compliance
| 5 March 2024 | Market Announcement 1/1 |
| ASX Limited | ASX Customer Service Centre 131 279 | asx.com.au |
5 March 2024
Melissa Kostopoulos
Compliance Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Ltd
Level 50, South Tower, Rialto 525 Collins St Melbourne VIC 3000
| By email: | TradingHaltsMelbourne@asx.com.au ListingsComplianceMelbourne@asx.com.au |
Dear Melissa
Request for Trading Halt - Immuron Limited
In accordance with ASX Listing Rule 17.1, Immuron Limited (ASX: IMC; NASDAQ: IMRN) (the Company) requests an immediate trading halt in respect of its securities. This trading halt is requested to allow Immuron to analyse and interpret data prior to making an announcement of Phase 2 IMM-124E clinical trial top-line results.
The Company requests that trading in its securities be halted until after the expected announcement is made or until the market opens on 7 March 2024, whichever is the earlier.
The Company is not aware of any reason why this trading halt request should not be granted or of any other information necessary to inform the market about the trading halt.
Please contact me if you require any further information.
Yours sincerely
Phillip Hains
Company Secretary
| Immuron Limited ABN 80 063 114 045 | Australia: +61 3 8892 4854 |
| www.immuron.com | USA and Canada: +1 (213) 817-5756 |